Travere Therapeutics, Inc. Quarterly Costs and Expenses in USD from Q3 2010 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Total costs of sales and operating expenses for the period.
Summary
Travere Therapeutics, Inc. quarterly/annual Costs and Expenses history and growth rate from Q3 2010 to Q3 2024.
  • Travere Therapeutics, Inc. Costs and Expenses for the quarter ending September 30, 2024 was $119M, a 8.2% decline year-over-year.
  • Travere Therapeutics, Inc. Costs and Expenses for the twelve months ending September 30, 2024 was $561M, a 9.93% increase year-over-year.
  • Travere Therapeutics, Inc. annual Costs and Expenses for 2023 was $533M, a 24.3% increase from 2022.
  • Travere Therapeutics, Inc. annual Costs and Expenses for 2022 was $429M, a 29.6% increase from 2021.
  • Travere Therapeutics, Inc. annual Costs and Expenses for 2021 was $331M, a 11.5% decline from 2020.
Costs and Expenses, Trailing 12 Months (USD)
Costs and Expenses, Quarterly (USD)
Costs and Expenses, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $561M $119M -$10.6M -8.2% Jul 1, 2024 Sep 30, 2024 10-Q 2024-10-31
Q2 2024 $571M $122M -$14.3M -10.5% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-01
Q1 2024 $586M $181M +$52.4M +40.8% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-06
Q4 2023 $533M $139M +$23.3M +20% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-20
Q3 2023 $510M $130M +$19M +17.2% Jul 1, 2023 Sep 30, 2023 10-Q 2024-10-31
Q2 2023 $491M $136M +$29M +27.1% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-01
Q1 2023 $462M $128M +$32.9M +34.5% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-06
Q4 2022 $429M $116M +$69.6M +150% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-20
Q3 2022 $360M $111M +$10.8M +10.8% Jul 1, 2022 Sep 30, 2022 10-K 2024-02-20
Q2 2022 $349M $107M +$17.2M +19.2% Apr 1, 2022 Jun 30, 2022 10-K 2024-02-20
Q1 2022 $332M $95.4M +$437K +0.46% Jan 1, 2022 Mar 31, 2022 10-K 2024-02-20
Q4 2021 $331M $46.4M -$123M -72.6% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-20
Q3 2021 $454M $99.9M +$29.4M +41.6% Jul 1, 2021 Sep 30, 2021 10-Q 2022-10-27
Q2 2021 $425M $89.9M +$18.4M +25.7% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 $407M $95M +$32.1M +51.1% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 $374M $170M +$94.7M +126% Oct 1, 2020 Dec 31, 2020 10-K 2021-03-01
Q3 2020 $280M $70.6M -$8.24M -10.5% Jul 1, 2020 Sep 30, 2020 10-Q 2021-10-29
Q2 2020 $288M $71.5M -$9.7M -11.9% Apr 1, 2020 Jun 30, 2020 10-Q 2021-07-29
Q1 2020 $298M $62.8M -$15M -19.2% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 $313M $74.9M +$26.1M +53.5% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-01
Q3 2019 $287M $78.8M +$2.52M +3.31% Jul 1, 2019 Sep 30, 2019 10-K 2021-03-01
Q2 2019 $284M $81.2M +$18.3M +29.2% Apr 1, 2019 Jun 30, 2019 10-K 2021-03-01
Q1 2019 $266M $77.8M +$21.5M +38.1% Jan 1, 2019 Mar 31, 2019 10-K 2021-03-01
Q4 2018 $244M $48.8M Oct 1, 2018 Dec 31, 2018 10-K 2020-02-24
Q3 2018 $76.3M Jul 1, 2018 Sep 30, 2018 10-K 2020-02-24
Q2 2018 $62.9M Apr 1, 2018 Jun 30, 2018 10-K 2020-02-24
Q1 2018 $56.3M Jan 1, 2018 Mar 31, 2018 10-K 2020-02-24
Q4 2012 $3.66K* +$143 Sep 1, 2012 Nov 30, 2012 10-Q 2013-03-06
Q3 2012 $3.5K* -$25 Jun 1, 2012 Aug 31, 2012 10-Q 2012-10-10
Q2 2012 $3.51K* -$15 Feb 29, 2012 May 31, 2012 10-Q 2012-08-08
Q4 2011 $3.52K* -$2.15K Sep 1, 2011 Nov 30, 2011 10-Q 2013-03-06
Q3 2011 $3.53K* -$3.1K Jun 1, 2011 Aug 31, 2011 10-Q 2012-10-10
Q2 2011 $3.52K* Mar 1, 2011 May 31, 2011 10-Q 2012-08-08
Q4 2010 $5.67K* Sep 1, 2010 Nov 30, 2010 10-Q 2012-01-11
Q3 2010 $6.63K* Jun 1, 2010 Aug 31, 2010 10-Q/A 2012-06-06
* An asterisk sign (*) next to the value indicates that the value is likely invalid.